絞り込み

18370

広告

Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.

著者 Seban RD , Nemer JS , Marabelle A , Yeh R , Deutsch E , Ammari S , Moya-Plana A , Mokrane FZ , Gartrell RD , Finkel G , Barker L , Bigorgne AE , Schwartz LH , Saenger Y , Robert C , Dercle L
Eur J Nucl Med Mol Imaging.2019 Jul 25 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)
An imaging-based stratification tool is needed to identify melanoma patients who will benefit from anti Programmed Death-1 antibody (anti-PD1). We aimed at identifying biomarkers for survival and response evaluated in lymphoid tissue metabolism in spleen and bone marrow before initiation of therapy.
PMID: 31346755 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード